Journal article

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

Fredrick R Schumacher, Ali Amin Al Olama, Sonja I Berndt, Sara Benlloch, Mahbubl Ahmed, Edward J Saunders, Tokhir Dadaev, Daniel Leongamornlert, Ezequiel Anokian, Clara Cieza-Borrella, Chee Goh, Mark N Brook, Xin Sheng, Laura Fachal, Joe Dennis, Jonathan Tyrer, Kenneth Muir, Artitaya Lophatananon, Victoria L Stevens, Susan M Gapstur Show all

Nature Genetics | NATURE PUBLISHING GROUP | Published : 2018

Grants

Awarded by US National Institutes of Health (NIH)


Awarded by NIH NCI


Awarded by European Community's Seventh Framework Programme


Awarded by Cancer Research UK


Awarded by NIH


Awarded by Post-Cancer GWAS Initiative


Awarded by Department of Defense


Awarded by European Commission's Seventh Framework Programme


Awarded by NIH Cancer Post-Cancer GWAS initiative


Awarded by National Health and Medical Research Council, Australia


Awarded by National Cancer Institute


Awarded by Swedish Cancer Foundation


Awarded by Linneus Centre grant - Swedish Research Council


Awarded by wedish Research Council


Awarded by Medical Research Council


Awarded by National Institute for Health Research


Awarded by The Danish Cancer Society


Awarded by The Francis Crick Institute


Awarded by NATIONAL CANCER INSTITUTE


Awarded by NATIONAL HUMAN GENOME RESEARCH INSTITUTE


Funding Acknowledgements

We pay tribute to Brian Henderson for his vision and leadership; he was a driving force behind the OncoArray project and he unfortunately passed away before seeing its fruition. We also thank the individuals who participated in these studies enabling this work.r Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) (U19 CA 148537 for the ELLIPSE project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract no. HHSN268201200008I. Additional analytical support was provided by NIH NCI U01 CA188392 (to F.A.S.).r Funding for the iCOGS infrastructure came from the European Community's Seventh Framework Programme under grant agreement no. 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, and C8197/A16565), the NIH (CA128978) and Post-Cancer GWAS Initiative (1U19 CA148537, 1U19 CA148065, and 1U19 CA148112; the GAME-ON initiative), the Department of Defense (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.r This work was supported by the Canadian Institutes of Health Research; the European Commission's Seventh Framework Programme grant agreement no. 223175 (HEALTH-F2-2009-223175); Cancer Research UK grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, and C16913/A6135; and NIH Cancer Post-Cancer GWAS initiative grant no. 1 U19 CA 148537-01 (the GAME-ON initiative).r We also thank the following for funding support: the Institute of Cancer Research and the Everyman Campaign, the Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), the Orchid Cancer Appeal, the National Cancer Research Network UK, and the National Cancer Research Institute (NCRI) UK. We are grateful for the support of NIHR funding to the NIHR Biomedical Research Centre at the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust.r The Prostate Cancer Program of Cancer Council Victoria also acknowledges grant support from the National Health and Medical Research Council, Australia (126402, 209057, 251533, 396414, 450104, 504700, 504702, 504715, 623204, 940394, and 614296), VicHealth, Cancer Council Victoria, the Prostate Cancer Foundation of Australia, the Whitten Foundation, PricewaterhouseCoopers, and Tattersall's. E.A.O., D.M.K., and E.M.K. acknowledge the Intramural Program of the National Human Genome Research Institute for support.r The BPC3 was supported by the NIH, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 to E.R., and U01-CA98758 to B.E.H., and the Intramural Research Program of the NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).r The CAPS GWAS study was supported by the Swedish Cancer Foundation (grant nos. 09-0677, 11484, and 12-823), the Cancer Risk Prediction Center (CRisP; http://ki.se/en/meb/crisp/), a Linneus Centre grant (contract ID 70867902) financed by the Swedish Research Council, and the Swedish Research Council (grant nos. K2010 70X-20430-04-3, and 2014-2269).r PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH.r A full description of funding and acknowledgements can be found in the Supplementary Note.